Lexicon Pharmaceuticals, Inc.
LXRX
$1.12
-$0.03-2.61%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,504.83% | 1,250.63% | 2,479.34% | 884.75% | 792.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,504.83% | 1,250.63% | 2,479.34% | 884.75% | 792.40% |
| Cost of Revenue | 53.46% | 13.72% | -6.30% | -24.03% | -29.82% |
| Gross Profit | 110.52% | 48.08% | 58.15% | 32.41% | 36.44% |
| SG&A Expenses | -39.39% | -11.17% | 17.20% | 45.35% | 72.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.44% | 5.12% | 25.88% | 37.92% | 54.27% |
| Operating Income | 45.77% | 10.48% | -8.52% | -35.02% | -51.93% |
| Income Before Tax | 40.32% | 8.41% | -13.15% | -37.08% | -54.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.32% | 8.41% | -13.15% | -37.08% | -54.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.32% | 8.41% | -13.15% | -37.08% | -54.61% |
| EBIT | 45.77% | 10.48% | -8.52% | -35.02% | -51.93% |
| EBITDA | 45.92% | 10.50% | -8.56% | -35.11% | -52.03% |
| EPS Basic | 57.15% | 37.70% | 19.54% | 0.62% | -13.88% |
| Normalized Basic EPS | 61.21% | 41.40% | 23.22% | 1.35% | -13.04% |
| EPS Diluted | 57.15% | 37.70% | 19.54% | 0.62% | -13.88% |
| Normalized Diluted EPS | 61.21% | 41.40% | 23.22% | 1.35% | -13.04% |
| Average Basic Shares Outstanding | 38.46% | 48.50% | 44.76% | 40.51% | 38.11% |
| Average Diluted Shares Outstanding | 38.48% | 48.50% | 44.76% | 40.51% | 38.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |